Biogen Inc (BIIB)
243.90
+2.15 +0.89%
NASDAQ
Nov 27, 13:58
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 14.26B |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | 30.21 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | 5.082B |
| Profitability | |
| Gross Profit Margin (Quarterly) | 86.70% |
| Profit Margin (Quarterly) | 20.78% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 0% |
| Price and Valuation | |
| Market Cap | 37.53B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 2.861 |
| PE Ratio | 8.073 |
| Price to Book Value | 3.489 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio | 0.6902 |
| Free Cash Flow (Quarterly) | 1.097B |
| Return on Equity | Upgrade |
View All BIIB News
News
-
WireHeadlineTime (ET)
-
Yahoo11/27 15:10
-
Yahoo11/27 13:18
-
MT Newswires11/27 13:09
-
MT Newswires11/27 11:45
-
Yahoo11/27 11:25
-
MT Newswires11/27 09:17
-
Yahoo11/27 08:50
-
Yahoo11/27 08:42
-
MT Newswires11/27 08:33
-
Yahoo11/27 08:04
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 01/29/2021 | Earnings | Biogen Inc Fourth Quarter Earnings for 2020 Release |
| 01/29/2021 08:00 EST | Misc | Biogen Inc Fourth Quarter Earnings Conference Call for 2020 |
| 10/21/2020 | Earnings | Biogen Inc Third Quarter Earnings Result for 2020 |
| 10/21/2020 08:00 EDT | Misc | Biogen Inc Third Quarter Earnings Conference Call for 2020 |
| 07/22/2020 08:00 EDT | Misc | Biogen Inc Second Quarter Earnings Conference Call for 2020 |
| 07/22/2020 | Earnings | Biogen Inc Second Quarter Earnings Result for 2020 |
| 06/03/2020 09:00 EDT | Misc | Biogen Inc Annual General Meeting for 2019 |
| 04/22/2020 08:00 EDT | Misc | Biogen Inc First Quarter Earnings Conference Call for 2020 |
| 04/22/2020 | Earnings | Biogen Inc First Quarter Earnings Result for 2020 |
| 02/06/2020 | Misc | Biogen Inc Annual Report for 2019 |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: http://www.biogen.com
- Investor Relations URL: https://www.biogen.com/en_us/investors.html
- HQ State/Province: Massachusetts
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Equity Style: Large Cap/Value
- Next Earnings Release: Jan. 29, 2021
- Last Earnings Release: Oct. 21, 2020
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 243.90 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| LMPFX | ClearBridge Aggressive Growth FI | 7.41% |
| BBH | VanEck Vectors Biotech ETF | 4.38% |
| VPMCX | Vanguard PRIMECAP Inv | 4.00% |
| HQL | Tekla Life Sciences Investors | 3.62% |
| IBB | iShares Nasdaq Biotechnology ETF | 3.48% |
| VHCOX | Vanguard Capital Opportunity Inv | 3.36% |
| HQH | Tekla Healthcare Investors | 3.08% |
| VPCCX | Vanguard PRIMECAP Core Inv | 3.02% |
| FBT | First Trust NYSE Arca Biotech ETF | 2.91% |
| POGRX | PRIMECAP Odyssey Growth | 2.83% |
| VGHCX | Vanguard Health Care Inv | 2.17% |
| FXH | First Trust Health Care AlphaDEX® ETF | 1.62% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- BIIB Tweets Stocktwits
Advertisement
